Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Optimal study design for pioglitazone in septic pediatric patients.

Sherwin CM, Ding L, Kaplan J, Spigarelli MG, Vinks AA.

J Pharmacokinet Pharmacodyn. 2011 Aug;38(4):433-47. doi: 10.1007/s10928-011-9202-8. Epub 2011 Jun 11.

2.

[Bioequivalence assessment of pioglitazone hydrochloride oral preparation by limited sampling strategy].

Ding JJ, Jiao Z, Li ZD, Shi XJ.

Yao Xue Xue Bao. 2006 Sep;41(9):893-8. Chinese.

PMID:
17111840
3.

Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes.

Christensen ML, Meibohm B, Capparelli EV, Velasquez-Mieyer P, Burghen GA, Tamborlane WV.

J Clin Pharmacol. 2005 Oct;45(10):1137-44.

PMID:
16172178
4.

Pharmacokinetic interactions between topiramate and pioglitazone and metformin.

Manitpisitkul P, Curtin CR, Shalayda K, Wang SS, Ford L, Heald D.

Epilepsy Res. 2014 Nov;108(9):1519-32. doi: 10.1016/j.eplepsyres.2014.08.013. Epub 2014 Aug 30.

PMID:
25219351
5.

Population pharmacokinetics and optimal design of paediatric studies for famciclovir.

Ogungbenro K, Matthews I, Looby M, Kaiser G, Graham G, Aarons L.

Br J Clin Pharmacol. 2009 Oct;68(4):546-60. doi: 10.1111/j.1365-2125.2009.03479.x.

6.

Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation.

van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD.

Pediatr Blood Cancer. 2014 Dec;61(12):2223-9. doi: 10.1002/pbc.25198. Epub 2014 Aug 30.

PMID:
25175364
8.

No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.

Smulders RA, Zhang W, Veltkamp SA, van Dijk J, Krauwinkel WJ, Keirns J, Kadokura T.

Diabetes Obes Metab. 2012 Oct;14(10):937-43. doi: 10.1111/j.1463-1326.2012.01624.x. Epub 2012 Jun 7.

PMID:
22587345
9.
10.

An evaluation of population D-optimal designs via pharmacokinetic simulations.

Hooker AC, Foracchia M, Dodds MG, Vicini P.

Ann Biomed Eng. 2003 Jan;31(1):98-111.

PMID:
12572660
11.
12.

A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.

Vaidyanathan S, Maboudian M, Warren V, Yeh CM, Dieterich HA, Howard D, Dole WP.

Curr Med Res Opin. 2008 Aug;24(8):2313-26. doi: 10.1185/03007990802259354.

PMID:
18786303
13.

Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.

Albers S, Meibohm B, Mir TS, Läer S.

Br J Clin Pharmacol. 2008 Apr;65(4):511-22. Epub 2007 Nov 8.

14.

A prospective population pharmacokinetic analysis of sapropterin dihydrochloride in infants and young children with phenylketonuria.

Qi Y, Mould DR, Zhou H, Merilainen M, Musson DG.

Clin Pharmacokinet. 2015 Feb;54(2):195-207. doi: 10.1007/s40262-014-0196-4.

15.
16.

The pharmacokinetics of pioglitazone in Thai healthy subjects.

Wittayalertpanya S, Chompootaweep S, Thaworn N.

J Med Assoc Thai. 2006 Dec;89(12):2116-22.

PMID:
17214065
17.
18.

Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

Serra D, He YL, Bullock J, Riviere GJ, Balez S, Schwartz S, Wang Y, Ligueros-Saylan M, Jarugula V, Dole WP.

Int J Clin Pharmacol Ther. 2008 Jul;46(7):349-64.

PMID:
18793589
19.

Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.

Aquilante CL, Wempe MF, Spencer SH, Kosmiski LA, Predhomme JA, Sidhom MS.

Pharmacotherapy. 2013 Sep;33(9):1000-7. doi: 10.1002/phar.1292. Epub 2013 May 26.

20.

The pharmacokinetics of pioglitazone in patients with impaired renal function.

Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompôr T, Eckland D.

Br J Clin Pharmacol. 2003 Apr;55(4):368-74.

Supplemental Content

Support Center